Latest Conference Articles

January 27th 2019, 11:44pm

PER® Winter Lung Cancer Conference

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses the current state of treatment in patients with non–small cell lung cancer.

January 27th 2019, 4:51am

PER® Winter Lung Cancer Conference

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses traditional and emerging treatment approaches for patients with mesothelioma.

January 27th 2019, 4:39am

PER® Winter Lung Cancer Conference

A growing focus on smaller oncogenic drivers in lung cancer has opened up new treatment options and many potential drugs in development for patients with less common alterations.

January 27th 2019, 12:45am

PER® Winter Lung Cancer Conference

The treatment paradigm for EGFR-mutant non–small cell lung cancer has grown significantly with many EGFR TKIs now available to treat patients with this disease.

January 27th 2019, 12:36am

PER® Winter Lung Cancer Conference

Rogerio Lilenbaum, MD, highlights the current treatment approaches for patients with EGFR-positive non–small cell lung cancer and shed light on the potential for immunotherapy in the space.

January 26th 2019, 10:20pm

PER® Winter Lung Cancer Conference

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses managing immune-related adverse events in lung cancer.

January 26th 2019, 9:38pm

PER® Winter Lung Cancer Conference

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the potential for immunotherapy in the treatment of patients with EGFR-positive non–small cell lung cancer.

January 22nd 2019, 1:21am

SGO Winter Meeting

Successful application of immunotherapy in endometrial cancer means identifying the patients with inflamed tumors who will respond to treatment and those who will not, and finding ways to treat noninflamed tumors with immunotherapy agents.

January 21st 2019, 10:31pm

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with previously untreated hepatocellular carcinoma lived twice as long if they responded to TKI therapy as compared with patients who did not achieve an objective response.

January 21st 2019, 7:48pm

Gastrointestinal Cancers Symposium (ASCO GI)

Jonathan R. Strosberg, MD, discusses the findings from the phase II KEYNOTE-158 trial investigating pembrolizumab in patients with advanced neuroendocrine tumors.

January 21st 2019, 2:08am

SGO Winter Meeting

Robert Coleman, MD, highlights recent advances made in gynecologic cancers and provide insight into ongoing research to move the needle forward.

January 20th 2019, 11:49pm

Gastrointestinal Cancers Symposium (ASCO GI)

The combination use of durvalumab and tremelimumab plus best supportive care prolonged median overall survival by 2.5 months compared with supportive care alone in patients with advanced refractory colorectal cancer.

January 20th 2019, 9:15pm

Gastrointestinal Cancers Symposium (ASCO GI)

The PD-L1 inhibitor durvalumab achieved objective responses in about a fourth of patients with microsatellite instability-high advanced solid tumors, including colorectal cancer.

January 20th 2019, 2:15pm

SGO Winter Meeting

Charles A. Leath III, MD, gyn oncologist at the University of Alabama at Birmingham, discusses the glaring unmet need in cervical cancer.

January 20th 2019, 1:29pm

SGO Winter Meeting

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses advances made in the treatment of ovarian cancer.

January 20th 2019, 6:04am

Gastrointestinal Cancers Symposium (ASCO GI)

Clinical outcomes with the combination of encorafenib, binimetinib, and cetuximab exceed historic data in patients with BRAF V600E-mutant metastatic colorectal cancer.

January 20th 2019, 5:58am

SGO Winter Meeting

For all the positive data associated with PARP inhibitors in patients with epithelial ovarian cancer who have known BRCA mutations and despite several agents winning FDA approval over the past few years, PARP inhibitors aren’t curing patients.

January 20th 2019, 12:28am

Gastrointestinal Cancers Symposium (ASCO GI)

The oral multi-kinase inhibitor regorafenib extended progression-free survival in patients with metastatic or unresectable biliary tract cancer who were previously treated with gemcitabine and a platinum-based chemotherapy.

January 19th 2019, 11:29pm

SGO Winter Meeting

Shannon Westin, MD, discusses the evolving role of PARP inhibitors in ovarian cancer, novel investigational agents, and the importance of molecular testing.

January 19th 2019, 10:49pm

Gastrointestinal Cancers Symposium (ASCO GI)

Josep M. Llovet, MD, PhD, discusses the results from the phase III REACH-2 study of ramucirumab as a second-line treatment of patients with advanced hepatocellular carcinoma.